Marker Therapeutics (MRKR) Depreciation & Amortization (CF) (2019 - 2023)

Marker Therapeutics (MRKR) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $818216.0 in Q1 2023.

• Depreciation & Amortization (CF) for Q1 2023 came in at $818216.0, up 41.97% year-over-year; the trailing twelve-month figure through Dec 2023 was $818216.0 (down 70.66% YoY), and the FY2022 annual result was $2.8 million, up 29.79% from the prior year.
• Depreciation & Amortization (CF) grew to $818216.0 in Q1 2023 per MRKR's latest filing, from $813110.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $819883.0 in Q3 2022 and troughed at $10514.0 in Q1 2019.
• A 5-year average of $373357.0 and a median of $502743.0 in 2021 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2021 and 2022: Depreciation & Amortization (CF) soared 1325.61% in 2021, then advanced 9.35% in 2022.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $34215.0 in 2019, then surged by 522.29% to $212916.0 in 2020, then surged by 165.12% to $564488.0 in 2021, then surged by 44.04% to $813110.0 in 2022, then gained by 0.63% to $818216.0 in 2023.
• Business Quant data shows MRKR's Depreciation & Amortization (CF) at $818216.0 in Q1 2023, $813110.0 in Q4 2022, and $819883.0 in Q3 2022.